Explore 3 Stock Ideas & Industry Insights Download Free Report

News

22nd Century Group (NASDAQ: XXII): The VLN Reduced-Nicotine Rollout in Focus

22nd Century Group manufactures, distributes and sells proprietary reduced-nicotine tobacco products and provides contractManufacturingfor other tobacco brands. Its flagship is VLN, a cigarette engineered to contain far less nicotine, marketed under an FDA Modified Risk Tobacco Product framework as a harm-reduction option. Through 2026 …

Vinay Lochav | 10 September 2026

Limitless X Holdings (OTC: LIMX): Rebuilding Sales in a Crowded Wellness Market

Limitless X Holdings is a diversified consumer packaged goods company focused on the nutrition, wellness and beauty sectors. Its model combines product development with direct-response advertising,Digital Marketingservices and direct-to-consumer e-commerce. Recent developments describe an effort to broaden the platform and stabilise the business: the …

Vinay Lochav | 10 September 2026

Vaxxinity (OTC: VAXX): What Investors Can Verify About the Deregistered Micro-Cap

Vaxxinity is a biotechnology company that built a platform aimed at turning chronic-disease treatment toward vaccine-like immunotherapies, historically targeting neurodegenerative conditions such as Parkinson's and Alzheimer's disease. The pivotal corporate development for the stock came in April 2024, when Vaxxinity announced its intention to …

Vinay Lochav | 10 September 2026

Lite Strategy (NASDAQ: LITS): Inside the Former Biotech's Pivot to a Litecoin Treasury

On September 10, 2025, MEI Pharma announced it had rebranded as Lite Strategy, Inc. and adopted the newNasdaqticker LITS. The move accompanied a strategic overhaul: the company closed a $100 million private placement in July 2025 to fund a digital-asset treasury built around Litecoin …

Vinay Lochav | 10 September 2026

Biomolecular Life Holdings (OTC: BIOM): A Look at the Rebranded Wellness Micro-Cap

Biomolecular Life Holdings is a small over-the-counter company positioning itself in the wellness and longevity space,Marketingpremium supplements it describes as developed using nutrigenomics and artificial intelligence, alongside services spanning precision nutrition and regenerative wellness technologies. The corporate history matters here: the entity traces back …

Vinay Lochav | 10 September 2026

TScan Therapeutics (NASDAQ: TCRX): Inside the Company's Strategic Reorganization

TScan Therapeutics is a Nasdaq-listed, clinical-stage biotechnology company developing T-cell receptor-engineered (TCR-T) cell therapies for cancer and other diseases. On September 2, 2026, TScan announced a strategic reorganization to concentrate on in vivo-engineered TCR-T therapy for solid tumors. The plan advances two candidates targeting …

Vinay Lochav | 10 September 2026

Heron Therapeutics (NASDAQ: HRTX): The CINVANTI Patent Ruling and What It Means

Heron Therapeutics is a Nasdaq-listed commercial-stage pharmaceutical company built around its proprietary Biochronomer drug-delivery technology. Its portfolio spans acute-care and oncology-supportive products, including ZYNRELEF and APONVIE in acute care and CINVANTI and SUSTOL in the oncology-supportive space. The pivotal recent development came on June …

Vinay Lochav | 10 September 2026

Zivo Bioscience (OTC: ZIVO): A Look at the Algae-Based Health and Agtech Developer

Zivo Bioscience develops therapeutic and nutritional products derived from proprietary algal cultures, targeting animal health, human health and dietary-supplement markets. Its intellectual property centers on proprietary algal strains and patented production techniques. A notable structural development came in May 2026, when the company transitioned …

Vinay Lochav | 10 September 2026

Atossa Therapeutics (NASDAQ: ATOS): Where the Breast-Cancer Pipeline Stands

Atossa Therapeutics is a Nasdaq-listed, clinical-stage biopharmaceutical company focused on breast cancer. Its lead asset is (Z)-endoxifen, an oral selective estrogen receptor modulator and degrader in Phase 2 development for breast-cancer treatment and risk reduction, with exploration in additional therapeutic areas. Through 2026 the …

Vinay Lochav | 10 September 2026

BNB Plus Corp (OTCQB: BNBX): From Applied DNA Sciences to a Crypto Treasury Strategy

BNB Plus Corp. is the rebranded successor to Applied DNA Sciences, a change unveiled in late 2025 as management pivoted toward a digital-asset treasury model centred on the BNB token. Crucially, the company did not abandon its scientific roots: it retains a biopharmaceutical and …

Vinay Lochav | 10 September 2026
Support

Hi! How can we help you today?

Loading…